One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Table of Contents
doi : 10.1016/S0923-7534(25)06222-2
Volume 36, Issue 12, December 2025, Pages i-ii
The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors
Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008☆
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma☆
A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer
Response to ‘A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer’
Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning
An unforeseen, existential threat to oncological research in Europe
Mechanism-enhanced population science: strengthening population studies through functional insights
SUNNIFORECAST trial design supported by real-world data in papillary renal cell carcinoma
Corrigendum to “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3�: [Ann Oncol 2024; 35: 718-727]
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)�: [Ann Oncol 26 (2015) 2168–2173]
Corrigendum to “Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population�: [Ann Oncol 36 (2025) 520-528]
